@article {Haas:2018:1072-3714:197,
title = "Associations among circulating colony-stimulating factor-1, estrogen, and bone mineral density in postmenopausal women: results from a randomized placebo-controlled trial",
journal = "Menopause",
parent_itemid = "infobike://wk/gme",
publishercode ="wk",
year = "2018",
volume = "25",
number = "2",
publication date ="2018-02-01T00:00:00",
pages = "197-201",
itemtype = "ARTICLE",
issn = "1072-3714",
eissn = "1530-0374",
url = "https://www.ingentaconnect.com/content/wk/gme/2018/00000025/00000002/art00013",
doi = "doi:10.1097/GME.0000000000000974",
keyword = "Osteoporosis, Women, Colony-stimulating factor 1, Bone",
author = "Haas, Andrea V. and Cong, Elaine and Simpson, Christine A. and Sukumar, Nitin and Deng, Yanhong and Insogna, Karl L.",
abstract = "
Objective:
This study addresses the relationship between circulating levels of colony-stimulating factor 1 (CSF-1) and rates of postmenopausal bone loss. The purpose was to test the hypothesis that CSF-1 levels would correlate with the rate of bone loss in estrogen-deficient
woman. We further hypothesized that estrogen replacement would eliminate this association.Methods:
This was an ancillary study to the parent Kronos Early Estrogen Prevention Study (KEEPS)a 4-year randomized placebo-controlled study that
evaluated the effects of estrogen therapy on cardiovascular endpoints. Women between of the ages of 42 and 58, who had been amenorrheic for 6 months and 36 months, were enrolled in KEEPS. Participants were randomized to conjugated equine estrogen 0.45mg daily, transdermal estradiol
50 micrograms weekly, or placebo.Results:
There was no correlation between serum levels of CSF-1 and bone mineral density at the spine, hip, or femoral neck in estrogen-deficient women (correlation 0.0017, P=0.99 for
spine; correlation 0.0010, P=0.0079 for hip, and correlation 0.0019, P=0.99 for femoral neck). There was also no significant correlation in the treatment group (correlation 0.0015, P=0.99; correlation 0.00024, P=0.99;
correlation 0.0011, P=0.99 at spine, hip, and femoral neck respectively).Conclusions:
This study did not demonstrate a meaningful relationship between circulating levels of CSF-1 and bone mineral density in either
the placebo group or estrogen-treated group. Although CSF-1 is required for osteoclastic bone resorption, our data suggest that circulating levels of the cytokine may not reflect this process.",
}